ADHD Linked to Significantly Higher Early Death Risk; Medication May Mitigate

Individuals diagnosed with attention-deficit/hyperactivity disorder (ADHD) face a nearly 71% higher overall risk of premature death compared to those without the condition, according to a new review published in JAMA Network Open. However, taking prescribed ADHD medication may offer a protective benefit, potentially lowering the overall risk of death.

Researchers analyzed data from 19 observational studies encompassing nearly 16 million individuals across three continents to assess the long-term mortality effects associated with ADHD. The review considered both unnatural causes of death, such as suicide and injuries, and natural causes, including cardiovascular disease and diabetes. Across all categories, people with ADHD exhibited elevated mortality rates.

The risk of death from suicide was nearly doubled, showing an 89% increase. The risk of dying from intentional or unintentional injuries, including accidents, was 55% higher. Furthermore, there was a 27% higher risk of death from natural causes among individuals with ADHD. This increased risk from natural causes was often linked to factors such as smoking, substance use, and executive function challenges that can impair the management of chronic conditions and adherence to treatment plans.

In an analysis examining the impact of medical treatment, individuals with ADHD who were taking prescribed medication demonstrated a 25% lower risk of death from any cause compared to those not on medication. This suggests that effective treatment could mitigate some of the behavioral and health risks associated with the condition.

Senior author Joshua Stott, professor of aging and clinical psychology at University College London, stated in a press release, "ADHD is not by definition a life-limiting condition, as the right support and treatment can help people live long and healthy lives." He added, "Our findings underscore the importance of ensuring that everyone who may have ADHD has access to accurate diagnosis and treatment."

The researchers acknowledged several limitations, including that all included studies were observational, establishing associations rather than direct cause-and-effect. The findings regarding ADHD medication were based on data from only three of the 19 studies, making them preliminary and derived from a smaller participant group.

First author Lucy Corrigan, a research assistant at the University of Liverpool’s Department of Psychology, noted, "Our findings provide early evidence to suggest that medication may play an important role in supporting the health of people with ADHD, but this is based on a small number of studies and further research is needed to clarify this link." She emphasized, "Medication is just part of the story; many people with ADHD benefit from comprehensive, long-term treatment and support."